Fig. 5From: Agnostic evaluation of ipilimumab and nivolumab association: a metanalysisOS Analysis. Figure shows the OS analysis on selected trials. The pooled HR favored the combination of nivolumab plus ipilimumab with respect to nivolumab alone (HR = 0.87; 95% CI: 0.763–0.997; P = 0.045). Fixed effect model—Heterogeneity not significant (P = 0.56)Back to article page